Sight Sciences' OMNIÂ® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Data
globenewswire.com
news
2022-05-31 00:00:00

Suppression of diurnal, or daily, fluctuations in IOP, is a significant and independent risk factor for the progression of glaucomaThese 12-month outcomes were also confirmed by results from a subset of the study, assessing the Hispanic patient population MENLO PARK, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives, today announced publication in Clinical Ophthalmology of its 12-month outcomes in the GEMINI study, including results from a Hispanic population subset.
